"Designing Growth Strategies is in our DNA"

Intravenous Immunoglobulin Market Size, Share & Industry Analysis By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Regional Forecast, 2018 - 2032

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI100593

 

Table of Content:

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. Pipeline Analysis
    2. Overview of Regulatory Scenario by Key Regions
    3. Key Industry Developments
    4. Number (Estimated) of Primary Immunodeficiency (PI) Patients by Key Countries
    5. Overview of Reimbursement Scenario
  5. Global Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis, Insights and Forecast – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis, Insights and Forecast – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis – By Country
      1. U.S.
      2. Canada
  7. Europe Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis – By Country/ Sub-Region
      1. U.K.
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis – By Country/ Sub-Region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    1. Key Findings / Summary
    2. Market Analysis – By Indication
      1. Primary Immunodeficiency
      2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      3. Guillain-Barré Syndrome (GBS)
      4. Immune Thrombocytopenic Purpura (ITP)
      5. Multifocal Motor Neuropathy (MMN)
      6. Others
    3. Market Analysis – By Form
      1. Liquid
      2. Lyophilized
    4. Market Analysis – By End User
      1. Hospitals
      2. Clinics
      3. Homecare
    5. Market Analysis – By Country/ Sub-Region
      1. GCC Countries
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2018)
    3. Competition Dashboard
    4. Comparative Analysis – Major Players
    5. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Shire (Takeda Pharmaceutical Company Limited)
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. CSL Behring
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Grifols, S.A.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Kedrion S.p.A
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Octapharma
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. Bio Products Laboratory Ltd.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Biotest AG
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. China Biologic Products Holdings, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. LFB SA
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      10. Shanghai RAAS Blood Products Co., Ltd.
        1. Overview,
        2. Products & Services,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  12. Strategic Recommendations
Intravenous Immunoglobulins Market Size, Share and Global Industry Trend Forecast till 2032
  • REPORT UPDATE
    IN PROCESS
  • 2019-2032
    (In Process)
  • 2023
    (In Process)
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase